載入...
A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901
Amrubicin, a third-generation synthetic anthracycline agent, has favorable clinical activity and acceptable toxicity for the treatment of patients with non-small cell lung cancer (NSCLC) and small cell lung cancer. We conducted this study to evaluate the efficacy and safety of amrubicin for advanced...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
AlphaMed Press
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3639531/ https://ncbi.nlm.nih.gov/pubmed/23442308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2012-0308 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|